Laboratory measures of hemostasis and fibrinolysis after intravenous administration of epsilon-aminocaproic acid in clinically normal horses and ponies.
OBJECTIVE
To determine whether epsilon-aminocaproic acid (EACA) administered IV affects hemostasis and fibrinolysis in clinically normal horses and ponies.


METHODS
20 clinically normal adult horses and ponies.


METHODS
Blood samples were collected 24 hours before (baseline) and 1 and 5 hours after i.v. administration of a low dose (30 mg/kg) or high dose (100 mg/kg) of EACA. Platelet count, fibrinogen concentration, prothrombin time, partial thromboplastin time (PTT), D-dimer concentration, alpha2-antiplasmin activity, and thrombin-antithrombin complex concentration were measured. Values at 1 and 5 hours were compared with baseline values.


RESULTS
hour after administration of a low dose of EACA, mean fibrinogen concentration was significantly lower than baseline concentration. Mean PTT was significantly shorter than the baseline value 5 hours after administration of a low dose of EACA. One hour after administration of 100 mg of EACA/kg, mean alpha2-antiplasmin activity was significantly higher than baseline activity. Mean fibrinogen concentration was significantly lower than baseline concentration 1 and 5 hours after administration of a high dose of EACA. Mean PTT was significantly shorter than the baseline value 5 hours after administration of a high dose of EACA.


CONCLUSIONS
i.v. administration of 30 and 100mg of EACA/kg to clinically normal horses significantly modified some laboratory measures of hemostasis, consistent with its known antifibrinolytic effects. Although enhanced clot maintenance and diminished bleeding were not directly assessed, the clinical use of EACA may benefit some patients.
Heidmann
Peter
P
Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331-4803, USA.
Tornquist
Susan J
SJ
Qu
Annie
A
Cebra
Christopher K
CK
D015119:Aminocaproic Acid / Q000008:administration & dosage*; D000818:Animals; D000990:Antithrombin III; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects* / Q000502:physiology; D006487:Hemostasis / Q000502:physiology*; D006736:Horses / Q000502:physiology*; D007262:Infusions, Intravenous / Q000662:veterinary; D008297:Male; D010314:Partial Thromboplastin Time / Q000662:veterinary; D010447:Peptide Hydrolases / Q000097:blood; D010976:Platelet Count / Q000662:veterinary; D011517:Prothrombin Time / Q000662:veterinary; D000979:alpha-2-Antiplasmin / Q000032:analysis
D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D005340:Fibrinogen; D010447:Peptide Hydrolases; D015119:Aminocaproic Acid